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A highlights lecture is never an easy task. First of all, it is difficult 
to summarize such enormous amount of scientific data presented 
during the congress. Secondly, it carries a risk that some omitted 
authors will be disappointed by avoiding their contribution. Finally, 
as stated by Cugowski et al. in his first presentation, „I know well 
that it’s too late to start all over again” [1]. Nevertheless, I must start 
and I am starting with an interesting presentation by our hosts here, 
in Lublin. They tested a new image acquisition regimen of para-
thyroid scans. Several protocols are used nowadays to visualize 
parathyroid adenomas using 99mTc-MIBI: planar subtraction scans, 
SPECT and SPECT/CT. Pachowicz et al. proposed a protocol in 
which at first 99mTc-pertechnetate SPECT of the neck and chest 
is registered followed by 99mTc-MIBI injection and another SPECT 
acquisition 15 min later. The acquisition is completed by CT scan 
without moving the patient off the gamma camera’s bed. The CT 
data of this acquisition are used for attenuation correction and 
anatomical correlation of both SPECT images. A presented selec-
tion of cases showed impressive results. Necessity of prolonged 
immobilization of the patient during the entire procedure seems to 
be the only disadvantage [2]. 
There were three independent studies dealing with the problem 
of thyroid incidentaloma in different imaging procedures. Giejda et 
al. reviewed myocardial perfusion images using 99mTc-MIBI in 354 
patients and found as many as 41 cases (11.6%) of tracer accumula-
tion in the thyroid gland. Thorough evaluation of all these cases led 
to detection of just one case of previously unknown differentiated 
thyroid carcinoma. The remaining cases represented different forms 
of benign thyroid disease [3]. In 1150 PET/CT scans with 
68Ga-DOTA-TATE focal thyroid activity was found by Kunikowska 
et al. in 12 cases (1.0%). Similarly, just one of them was caused by 
differentiated thyroid cancer [4]. Finally, among 6614 patients who 
had had PET/CT scans using 18F-FDG, 122 (2.3%) had focal tracer 
accumulation in the thyroid gland. 29.2% of evaluable cases were 
finally diagnosed with thyroid malignancies [5]. So, what we learned 
from these three retrospective analyses is that, surprisingly, thyroid ac-
cumulation is seen most frequently at 99mTc-MIBI scans (perhaps due 
to the presence of free technetium), but it is almost always caused by 
benign disease. Thyroid incidentalomas are rare in PET/CT scans (both 
68Ga-DOTA-TATE and 18F-FDG), but if they occur in 18F-FDG scans, the 
risk of differentiated thyroid carcinoma is relatively high.
Three interesting contributions from Białystok about radioio-
dine treatment of benign thyroid disease were presented, both 
performed on large patient cohorts. One of them, performed in 700 
patients with Graves’ disease, analyzed retrospectively different 
factors influencing the efficacy of radioiodine therapy. After 1 year 
of follow-up, the highest success rate was observed in patients with 
goiters of less than 50 ml who received the dose of 150 Gy. In 
patients with larger goiters (> 50 ml) required 200 Gy to treat hyper-
thyroidism [6]. In another presentation, the problem of radioiodine 
therapy in subclinical hyperthyroidism was evaluated. Abdelrazek 
et al. could present excellent results of the treatment with complete 
euthyroid status achieved in as many as 94% of patients with 
nodular goiter and in 99% of patients with toxic adenoma [7]. 
According to the authors, the success of therapy should be at-
tributed to strict individualization of radioiodine dose estimation 
including calculation of effective half-life of radioiodine and proper 
preparation of patients. Finally, Mojsak et al. shared with us their 
experiences with rhTSH to improve efficacy of radioiodine therapy 
in patients with non-toxic nodular goiter who had presented with low 
iodine uptake. Injection of rhTSH was able to increase iodine uptake 
from 33% at baseline to 75%. It resulted in better reduction of thyroid 
volume in comparison to the control group that was treated using 
radioiodine without rhTSH (48% vs. 31% of volume reduction) [8]. 
As usually, there were several reports concerning neuroen-
docrine tumors (NETs). Regarding the classical imaging of NETs, 
a nice overview of 99mTc-HYNIC-TOC scintigraphy based on a huge 
number of 1200 scans was delivered by Ćwikła et al. [9]. In dif-
ferent clinical settings (staging, restaging, unknown primary etc.) 
sensitivity and specificity were as high as 90–100%. Somatostatin 
receptor scintigraphy is not that effective in all NETs. In insulinoma, 
the expression of somatostatin receptors is relatively low. Therefore, 
we were glad to hear good news from Cracow about recent pos-
sibilities of tumor visualization using radiolabeled analogs of GLP-1 
[10]. Hubalewska-Dydejczyk et al. presented very encouraging 
images obtained with 99mTc-exendin-4 and 111In-exendin-4. These 
newly developed analogs were tested in 55 patients with insulinoma 
or some other NETs, showing high diagnostic accuracy. 
“Do we need 18F-FDG PET/CT to qualify a patient with NET to 
PRRT?” — this question was raised by Kunikowska et al. In order 
to provide the answer, she analyzed 30 patients who had PET/CT 
with both radionuclides: 18F-FDG and 67Ga-DOTA-TATE. As we 
would expect the patients with positive 18F-FDG examination had 
worse prognosis when it comes to the progression-free survival and 
overall survival [11]. So, the answer was: yes, 18F-FDG is useful, 
especially for prognosis.
With regard to the treatment of NETs, an elegant, randomized 
study of long acting somatostatin analogs as consolidation therapy 
after peptide receptor radionuclide therapy (PRRT) in advanced 
NETs was presented by the group from Oncology Centre in Gliwice 
[12]. In as many as 79 patients subjected to PRRT followed by con-
tinuous “cold” analog treatment, the results of therapy in terms of 
time-to-progression were compared with 46 patients who did not 
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receive the “cold” analog. Surprisingly, there was no statistical 
difference after mean follow-up of 34 months post PRRT. These re-
sults, as soon as they are published, should be seriously taken into 
account in the discussion on the treatment of disseminated NETs. 
Thyroid cancer was discussed in several presentations. One 
of them, originating from Belarus, was dedicated to children 
with thyroid cancer after Chernobyle nuclear accident. The new 
epidemiologic data provided by Baranovsky and Demidchyk [13], 
showed that young patients with irradiation-related thyroid cancer 
had excellent survival (99% in 10 years) despite regular occurrence 
of pulmonary metastases (97.5%) and quite frequent non-complete 
remission after surgery and RIT.
18F-FDG PET/CT evaluation of adrenal lesions has always been 
an interesting issue. In another study by Kunikowska et al., different 
imaging parameters were analyzed in 102 non-functioning adrenal 
tumors that were subsequently surgically removed [14]. Among 
these parameters (e.g. Hounsfield units, tumor diameter), two were 
found to be of prognostic value. Maximal standardized uptake value 
(SUVmax) above 5.2 and adrenal-to-liver SUVmax ratio above 1.53 
were indicating the malignant character of the lesion. Moreover, the 
latter parameter was found to be an independent prognostic factor. 
False-positive and false-negative results of PET/CT using 
18F-FDG in patients suspected for recurrence of colorectal 
cancer were discussed by Fijołek-Warszewska et al. [15]. The 
authors found ca. 5% of false-positive findings caused by me-
diastinal lymph-nodes activity, FDG uptake in the vicinity of the 
colon anastomosis and by intestinal infestation. Another 5% of the 
scans were false-negative. The undetected lesions were located in 
the brain, around the bladder and in the liver (small metastases). 
Performing PET/CT shortly after chemotherapy did also cause 
false-negative scans.
One of a few presentations addressing the issue of treatment 
monitoring by PET/CT was presented by colleagues from the same 
center in Warsaw. Response to neoadjuvant chemotherapy in 
young patients with sarcomas originating in bones was evaluated 
with 18F-FDG PET/CT [16]. Decrease of SUVmax between initial 
and post-therapy scans images showed good correlation with the 
histopathological assessment of tumor necrosis.
Nobody knows how it happened that in two cities, Cracow 
and Poznan, the same problem was independently studied. In 
both contributions, ovarian cancer recurrence in correlation with 
CA-125 marker level was evaluated using 18F-FDG PET/CT. Both 
groups have found that the grade of CA-125 elevation does not 
predict the localization of the recurrence or metastases [17, 18]. Ad-
ditionally, Fularz et al. defined the cut-off value of CA-125 concentra-
tion of 17.6 U/ml to optimize the diagnostic accuracy of PET/CT [18]. 
Patients with marker levels above this value are likely to have a posi-
tive PET/CT scan, showing recurrence of ovarian cancer.
Other PET tracers are studied in the PET/CT center in Byd-
goszcz. 18F-FLT was used to evaluate neoadjuvant chemotherapy in 
35 patients with breast cancer. SUVmax reduction did not correlate 
with the reduction of Ki-67 proliferation index [19]. In patients with 
prostate cancer, the same group lead by B. Małkowski reported that 
11C-acetate PET/CT showed higher sensitivity in the detection of 
bone metastases in comparison to classical bone scintigraphy [20]. 
Several presentations during this congress were devoted to 
radionuclide therapy. Łuka et al. summarized their experience with 
radiosynovectomy in patients with psoriatic arthritis. According to 
them, the first course of radiosynovectomy of the knee is frequently 
ineffective [21]. Fortunately, the patients usually respond to the 
second course of radiosynovectomy performed 6 months later. 
Dosimetric measurement of radiosynovectomy performed with 90Y 
is difficult due to beta-emission of this radionuclide. However, two 
possibilities of dosimetric evaluation were proposed by two groups. 
Zorga et al. injected intraarticularly 99mTc-sulfur colloid together with 
90Y-colloid in patients with juvenile arthritis, and assessed distribu-
tion of the radionuclide using a gamma camera [22]. Chojnowski 
et al. proposed PET/CT registration of the treated knee joints 4–5 
days after injection of 90Y [23].
A novel radioembolization regimen in patients with liver me-
tastases was discussed in details by a Polish-Canadian group 
formed by J. Ćwikła (Olsztyn), M.L. Nowicki (Warsaw) and A. Celler 
(Vancouver). Their studies are concentrated on 188-rhenium micro-
spheres instead of commonly used 90Y spheres. 188Re has many 
advantages over 90Y; one of them is gamma-emission. Dosimetry 
using SPECT technique showed correlation between mean tumor 
dose and overall survival. The treatment was well-tolerated and fur-
ther clinical experience is required to optimize the treatment [24, 25]. 
Bączyk et al. presented new data collected on a group of 
187 patients with bone metastases of prostate cancer treated 
with 153Sm-EDTMP. The group found that adjuvant treatment with 
intravenous bisphosphonates did improve analgesic effect of 
153Sm-EDTMP in mixed, but not in osteoblastic metastases that 
are present actually in majority of the patients [26]. The same au-
thors also addressed the rather rarely studied issue of psychologi-
cal impact of radionuclide therapy in the palliative setting. Based 
on a well-designed study protocol, the group was able to provide 
evidence that 153Sm-EDTMP therapy, by its significant analgesic 
effect, markedly reduces depression, anxiety and aggressive 
behavior [27]. 
Several interesting studies were presented in cardiological 
sessions of the congress. Kobylecka et al. studied the impact of 
glucose concentration on the quality of myocardial 18F-FDG PET/CT 
surprisingly finding no correlation at all [28]. In a study by Siennicki 
et al. clear evidence of the positive impact of attenuation correction 
on the sensitivity and specificity of myocardial perfusion imaging 
using 99mTc-MIBI was presented on a cohort of 107 patients [29]. 
This message will be welcome by the manufacturers of SPECT/CT 
scanners: the attenuation correction does really work in the heart 
studies…
Another study from Łódź considered the shortening of 
SPECT/CT acquisition time by half in order to enhance scanner’s ca-
pacity [30]. The authors found that although the image quality 
was satisfactory and the results of global myocardial contractility 
were comparable in “short” and “normal” acquisitions, the evalu-
ation of perfusion was slightly different in both regimens leading 
to some false clinical conclusions. Thus, shorter acquisition is not 
recommended. I would add that it is completely unnecessary as the 
authorities extend the working time in nuclear medicine and radiol-
ogy department in Poland this year…
Our community is gathering experience with gamma cam-
eras equipped with cadmium-zirconium detectors (CZD). Piszczek 
et al. found that prone position of the patient during myocardial 
perfusion data acquisition eliminates perfusion artifacts, especially 
in the inferior wall of the left ventricle. Prone position modified diag-
nosis in as many as 50% of the patients [31]. Myocardial adrenergic 
activity was examined by the congress organizer, B. Chrapko, in 
patients with chronic renal failure and with atrial fibrillation using 
123I-MIBG scintigraphy. She found that both patient groups had 
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increased myocardial tracer accumulation with higher activity in 
the group with atrial fibrillation [32]. 
Radionuclide diagnosis of pulmonary embolism (PE) re-
mains a hot issue with the introduction of novel imaging techniques. 
Mazurek et al. presented convincing data on the use of SPECT/CT to 
evaluate pulmonary perfusion in a group of 84 patients suspected of 
PE [33]. They reported that SPECT/CT acquisition of perfusion ima-
ges showed better diagnostic performance in comparison to planar 
images and SPECT images alone. Moreover, ventilation scans did 
not provide any additional value to the diagnosis obtained with 
SPECT/CT, so they concluded that ventilation scans could be avoid-
ed. On the contrary, in a study by Kovacević-Kuśmierek et al., lung 
perfusion acquired with SPECT/CT was not advantageous over planar 
images in the prognosis of respiratory function in patients planned 
for lobectomy or pulmonectomy due to lung cancer [34].
Another group from Łódź defined pharmacokinetic parame-
ters of 99mTc-ethylenecystein (EC) used for the dynamic renal 
scans as an alternative to 99mTc-MAG3. They found that both, mean 
renal transit time and parenchymal transit time are shorter in case 
of EC than for MAG3 and DTPA [35].
There were only few abstracts dealing with neuroimaging. 
One of them, by Nocuń et al., reported that one of the automatic 
software designed for the evaluation of cerebral perfusion SPECT 
was sufficiently reliable when larger perfusion lesions were present. 
Visual inspection of the images, however, seemed more accurate 
in case of smaller defects [36].
As usually, the congress gathered many highly professional 
presentations in the field of radiopharmacy, mostly contributed by 
the National Institute of Nuclear Research. It is difficult to summarize 
them here, due to highly specialistic character of the presented 
data. One of the studies concentrated on the development of gas-
trin analogs labeled with radiometals (90Y, 177Lu and 68Ga) [37]. The 
molecular structure of the complexes is dependent on the metal 
used. Another important issue is the development of alternative 
methods of production of technetium. The project under the aus-
pices of International Atomic Energy Agency deals with obtaining 
99mTc by bombarding enriched 100Mo with protons. As reported by 
Cieszykowska et al., the scientists work on the method of prepara-
tion of molybdenum target and recycling of 100Mo after obtaining 
99mTc from the target [38]. 
Physicists provided also interesting contribution to the con-
gress. Tomaszuk et al. worked on the optimization of PET/CT 
protocol aimed at the reduction of dose equivalent using phantom 
studies. They found that modification of CT current and voltage did 
not influence PET reconstruction and SUV values of large lesions. 
In case of smaller lesions, automatic current modulation was of 
special value [39]. Different methods of image reconstruction were 
studied on phantoms and on patients by Wyszomirska et al. They 
found that the method of reconstruction had little impact on the 
evaluation of the images. Differences of SUV measurements using 
various reconstruction protocols were significant only in case of 
higher SUV values [40].
Budzyńska et al. measured the efficacy of lead shielding 
coats worn by the staff. The results showed that 0.5 mm layer of 
lead in the protecting coats is quite efficient in case of low energy 
gamma radiation. The efficacy is even better if the radiation source 
is located in patient’s body [41]. It was explained that radiation scat-
tering decreases the photons’ energy, leading to a higher reduction 
of radiation dose on the other side of the tested shielding. 
Interesting findings were published by Dziel et al. They compared 
measurements of activity of 89Sr and 90Y in different counters dissemi-
nated across the country. The differences between the measured 
values and the actual calibrated activity were up to 20–31% [42].
So we could conclude that not all is true what we are measur-
ing. Moreover, Izabela Trojanowska disclosed at the opening of the 
congress, “truth and lies equally rule my entire life” [43]. Should 
this hold true for the whole content of our congress, only half of the 
information summarized by me is correct. Which half is it? I do not 
know. I am leaving that to you to decide... Thank you for your attention.
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